Stay updated on LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial

Sign up to get notified when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:57:43.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed study criteria for a clinical trial involving pembrolizumab and low-dose interleukin-2 for patients with advanced melanoma and renal cell carcinoma. Additionally, the principal investigator's name has been removed, and the revision number has been updated.
    Difference
    30%
    Check dated 2025-04-16T02:09:34.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-08T23:46:34.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-03-03T22:26:12.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    The webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.
    Difference
    2%
    Check dated 2025-02-10T10:06:29.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T08:49:21.000Z thumbnail image

Stay in the know with updates to LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.